2016;4:2050312116662414. 196. Ho MH, Ho CW, Cheung E, et al. Continuation of dabigatran therapy in "real-world" practice in Hong Kong. PloS One. 2014;9(8): e101245. 197. Li XS, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial brillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117(6):1072-1082. 198. Bai Y, Shi XB, Ma CS, Lip GYH. Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban. Am J Cardiol. 2017;120(9):1689-1695. 199. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17(4):514-523. 200. Wang KL, Chiu CC, Su-Yin Tan D, et al. Once- or twice-daily non- vitamin K antagonist oral anticoagulants in Asian patients with atrial brillation: a meta-analysis of randomized controlled trials. J Formos Med Assoc. 2017;116(8):591-598. 201. Chan PH, Huang D, Hai JJ, et al. Stroke prevention using dabigatran in elderly Chinese patients with atrial brillation. Heart Rhythm. 2016;13(2):366-373. 202. Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial brillation undergoing percutaneous coronary intervention: a North American Perspective-2016 Update. Circ Cardiovasc Interv. 2016;9(11). 203. Lane DA, Aguinaga L, Blomstrom-Lundqvist C, et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Paci c Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electro siologia (SOLEACE). Europace. 2015;17(12):1747-1769. 204. Ruff CT, Giugliano RP, Antman EM. Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of speci c reversal agents. Circulation. 2016;134(3):248-261. 205. Heidbuchel H, Verhamme P, Alings M, et al. 